Dave & Buster’s Reports Second Quarter 2025 Financial Results DALLAS, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster's” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its second quarter of fiscal 2025 ended August 5, 2025. Second Quarter 2025 Financial Summary Second quarter revenue was $557.4 million, a .05% increase compared to the second quarter of fiscal 2024.Comparable store sales decreased 3.0% compared to the same calendar period in fiscal 2024...
Dave & Buster’s Entertainment, Inc. to Report Second Quarter 2025 Financial Results on September 15, 2025 DALLAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner and operator of entertainment and dining venues, today announced that it will report financial results for its second quarter ended August 5, 2025 after the market closes on Monday, September 15, 2025. Management will host a conference call to discuss these results on Monday, September 15, 2025, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New York, NY. The Compan...
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – ...
Dave & Buster’s Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Dave & Buster’s Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster’s” or “the Company”), an owner and operator of entertainment and dining venues, announced today that the Company made awards of stock options (“Options”) and performance stock units (“PSUs”) to Tarun Lal, as a material inducement to Mr. Lal joining the Company as its Chief Executive Officer. The awards were approved by the Board in accordance with Listing Rule 5635(c)(4) of the corporate governance r...
Moody's Ratings (Moody's) assigned a B2 rating to Clear Channel Outdoor Holdings, Inc.'s (Clear Channel or the company) planned senior secured notes issuance. All other ratings are unchanged including its Caa1 Corporate Family Rating (CFR), Caa1-PD Probability of Default Rating (PDR), B2 senior secu...
Dave & Buster’s Appoints Tarun Lal as Chief Executive Officer DALLAS, July 15, 2025 (GLOBE NEWSWIRE) -- Dave & Buster’s Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster’s” or “the Company”), an owner and operator of entertainment and dining venues, today announced that the Board of Directors has appointed Tarun Lal as Chief Executive Officer and as a member of the Board of Directors effective July 14, 2025. “After a careful and comprehensive search, the Board is thrilled to announce Tarun as our next CEO,” said Kevin Sheehan, Chairman of the Board and Interim CEO. “Tarun is a talente...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
20-Day MA Supports Holding on SPX, QQQ, IWM The S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM) each continue to hold above short-term support at their respective 20-day MAs (currently 5966 on SPX, $526.50 on QQQ, and $208.75 on IWM) -- and have not closed below their 20-day MAs for two months. As long as 20-day MA supports hold, our near-term bullish outlook that we have had since our 4/22/25 Compass remains intact. We will need to see breakdowns below 20-day MA supports in order to ex...
Dave & Buster’s Announces Promotion of Les Lehner to Chief Development Officer DALLAS, June 13, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), ("Dave & Buster's" or "the Company") today announced that it has promoted Les Lehner to the position of Chief Development Officer. Mr. Lehner most recently served as Chief Procurement Officer and Head of Main Event Development. In connection with this promotion, the Company announced that John Mulleady, current Chief Development Officer, will retire effective as of the close of business on October 23, 2025. Effective...
Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in li...
Cabaletta Bio Announces Proposed Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.